PROVIDENCE PORTLAND MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $68.2M
- Transactions
- 4,208
- Companies
- 40
- Average per transaction
- $16,217
Who reported the payments
| Pfizer | $19,862,251 |
| Merck | $9,267,787 |
| E.r. Squibb & Sons, L.L.C. | $7,211,243 |
| Janssen Research & Development, LLC | $4,314,689 |
| AstraZeneca | $4,101,879 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,711,625 |
| Seagen Inc. | $2,262,511 |
| Incyte Corporation | $2,203,107 |
| Bristol Myers Squibb | $2,004,803 |
| Regeneron | $1,731,485 |
| Clinigen, Inc. | $1,613,341 |
| Novartis | $1,406,518 |
| Array Biopharma Inc | $1,076,731 |
| Eli Lilly | $951,924 |
| Hoffmann-la Roche Limited | $841,585 |
| Exelixis Inc. | $798,080 |
| Beigene, Ltd. | $651,834 |
| Daiichi Sankyo Inc. | $642,029 |
| Medtronic | $512,698 |
| Genentech, Inc. | $335,402 |
| Janssen Scientific Affairs, LLC | $333,320 |
| Macrogenics, Inc. | $299,789 |
| Modernatx, Inc. | $249,332 |
| F. Hoffmann-la Roche AG | $223,314 |
| Astrazeneca UK Limited | $212,221 |
| Bavarian Nordic A/s | $190,900 |
| Boehringer Ingelheim | $185,930 |
| Alkermes, Inc. | $170,441 |
| AbbVie | $160,425 |
| Astellas Pharma Global Development | $150,085 |
| Gilead | $146,726 |
| Coherus Oncology, Inc. | $136,280 |
| Beone Medicines USA, Inc. | $124,748 |
| Iovance Biotherapeutics, Inc. | $111,029 |
| Taiho Oncology, Inc. | $105,894 |
| Covidien LP | $100,000 |
| Otsuka Pharmaceutical Co., Ltd. | $87,275 |
| Smith+Nephew | $65,559 |
| Amgen | $62,580 |
| Abbott | $52,527 |